Report LibraryAll Reports
Datamonitor Healthcare Oncology: Acute Myeloid Leukemia (AML) Disease Coverage
Retail Price: $22,000.00*BioMedTracker Subscriber Price: $15,000.00 - click here to log in
December 04, 2017Acute myeloid leukemia (AML) is a hematological malignancy characterized by the proliferation of myeloid blast cells in blood and bone marrow. There has been little change to standard treatment for AML, which is typically based on cytarabine chemotherapy with an anthracycline. Although patients aged <60 years may achieve remission with induction therapy, most patients will relapse, and the prognosis worsens with age.
This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, and Pipeline modules.
|Disease Group Covered:||Oncology|